Stimulation of Nucleotide Oligomerization Domain and Toll-Like Receptors 2 to Enhance the Effect of Bacillus Calmette Guerin Immunization for Prevention of Mycobacterium Tuberculosis Infection: Protocol for a Series of Preclinical Randomized...

Overview

Journal JMIR Res Protoc

Publisher JMIR Publications

Specialty General Medicine

Date 2019 Jun 15

PMID 31199313

Citations 1

Authors

Michael Eisenhut

Affiliations

Soon will be listed here.

Abstract

Background: Bacillus calmette guerin (BCG) immunization has been associated with a reduction in Mycobacterium tuberculosis (MTB) infection. BCG immunization has been shown to enhance innate immunity. This effect of BCG can be explained by an enhancing effect on innate immunity.

Objective: This study aimed to test the following hypotheses: (1) BCG immunization can prevent infection with MTB, (2) prevention of infection occurs via stimulation of NOD2 (nucleotide oligomerization domain) and toll-like receptors 2 (TLR2), and (3) the effect of BCG immunization on prevention of infection with MTB can be enhanced by giving stimulators of NOD2 and TLR2.

Methods: To detect the influence of immunization on infection rates, the ultralow dose (ULD) infection model is used. The infection rate of mice vaccinated with BCG and exposed after 6 weeks to ULD of MTB and unvaccinated mice are compared via cultures of lung homogenates and interferon (IFN) gamma release assay. If a reduced infection rate by BCG immunization is confirmed, the experiment is repeated by giving BCG combined simultaneously or in time sequence with the enhancers of innate immunity murabutide or beta-glycan. The influence of murabutide or beta-glycan alone on infection rates is investigated. To quantify the contribution of innate immunity levels of tumor necrosis factor, IFN gamma expression, histone H3 K4me3 trimethylation, and concentrations of monocytes with features of activation of innate immunity as defined by the Ly6Chigh as well as CD11b positive phenotype in immunized versus unimmunized infected and uninfected mice in the various immunization protocols is compared. The experiments will be repeated with prior application of the inhibitors of epigenetic programming of innate immunity histone methyltransferase inhibitor 5'-deoxy-5'-methylthio-adenosine and histone acetyl transferase inhibitor epigallocatechin-3-gallate. The influence of BCG on innate immunity is further corroborated by a prospective observational study in human infants.

Results: Investigations of derivatives of muramyl dipeptide (MDP) to enhance early immunity in the C57BL/6 mouse strain (mice aged 7 weeks) by another group used 300 micrograms per mouse of oil-associated 6-0-mycoloyl-N-acetylmuramyl-L-alanyl-D-isoglutamine (mycol-MDP) 50/50 mixed with Freund's incomplete adjuvant. Comparison of colony-forming unit (CFU) count in the lungs 3 weeks after aerosol challenge with Mycobacterium bovis of groups (n=5) between groups receiving mycol-MDP in oil emulsion (see above) versus controls (n=5) showed a significantly lower CFU count of 94.5 x106 (SD 22.0) in cases versus controls with 204.0 X 106 (SD 77.6). It is important to note that after elimination of T-cells in this model, a reduction of CFU in lungs of mice treated with mycol-MDP persisted albeit without statistical significance, which was possibly related to the small number of animals used.

Conclusions: Demonstration of a reduction of MTB infection by enhancement of innate immunity could show a new approach to improving vaccine efficacy against this pathogen.

International Registered Report Identifier (irrid): PRR1-10.2196/13045.

Citing Articles

NOD2/RIG-I Activating Adjuvant Enhances the Efficacy of BCG Vaccine Against Tuberculosis in Mice.

Khan A, Singh V, Mishra A, Soudani E, Bakhru P, Singh C Front Immunol. 2020; 11:592333.

PMID: 33365029 PMC: 7751440. DOI: 10.3389/fimmu.2020.592333.

References

Liu X, Xu Y, Hardy L, Khammanivong V, Zhao W, Fernando G . IL-10 mediates suppression of the CD8 T cell IFN-gamma response to a novel viral epitope in a primed host. J Immunol. 2003; 171(9):4765-72. DOI: 10.4049/jimmunol.171.9.4765. View

Filaci G, Fravega M, Negrini S, Procopio F, Fenoglio D, Rizzi M . Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28- T cells and inhibit both T-cell proliferation and CTL function. Hum Immunol. 2004; 65(2):142-56. DOI: 10.1016/j.humimm.2003.12.001. View

Gutierrez M, Master S, Singh S, Taylor G, Colombo M, Deretic V . Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell. 2004; 119(6):753-66. DOI: 10.1016/j.cell.2004.11.038. View

Uehori J, Fukase K, Akazawa T, Uematsu S, Akira S, Funami K . Dendritic cell maturation induced by muramyl dipeptide (MDP) derivatives: monoacylated MDP confers TLR2/TLR4 activation. J Immunol. 2005; 174(11):7096-103. DOI: 10.4049/jimmunol.174.11.7096. View

Ferwerda G, Girardin S, Kullberg B, Le Bourhis L, de Jong D, Langenberg D . NOD2 and toll-like receptors are nonredundant recognition systems of Mycobacterium tuberculosis. PLoS Pathog. 2005; 1(3):279-85. PMC: 1291354. DOI: 10.1371/journal.ppat.0010034. View

Yadav M, Schorey J . The beta-glucan receptor dectin-1 functions together with TLR2 to mediate macrophage activation by mycobacteria. Blood. 2006; 108(9):3168-75. PMC: 1895517. DOI: 10.1182/blood-2006-05-024406. View

Roth A, Stensballe L, Garly M, Aaby P . Beneficial non-targeted effects of BCG--ethical implications for the coming introduction of new TB vaccines. Tuberculosis (Edinb). 2006; 86(6):397-403. DOI: 10.1016/j.tube.2006.02.001. View

Martineau A, Newton S, Wilkinson K, Kampmann B, Hall B, Nawroly N . Neutrophil-mediated innate immune resistance to mycobacteria. J Clin Invest. 2007; 117(7):1988-94. PMC: 1904316. DOI: 10.1172/JCI31097. View

Yang Y, Yin C, Pandey A, Abbott D, Sassetti C, Kelliher M . NOD2 pathway activation by MDP or Mycobacterium tuberculosis infection involves the stable polyubiquitination of Rip2. J Biol Chem. 2007; 282(50):36223-9. DOI: 10.1074/jbc.M703079200. View

10.

Divangahi M, Mostowy S, Coulombe F, Kozak R, Guillot L, Veyrier F . NOD2-deficient mice have impaired resistance to Mycobacterium tuberculosis infection through defective innate and adaptive immunity. J Immunol. 2008; 181(10):7157-65. DOI: 10.4049/jimmunol.181.10.7157. View

11.

Eisenhut M, Paranjothy S, Abubakar I, Bracebridge S, Lilley M, Mulla R . BCG vaccination reduces risk of infection with Mycobacterium tuberculosis as detected by gamma interferon release assay. Vaccine. 2009; 27(44):6116-20. DOI: 10.1016/j.vaccine.2009.08.031. View

12.

Sable S, Cheruvu M, Nandakumar S, Sharma S, Bandyopadhyay K, Kellar K . Cellular immune responses to nine Mycobacterium tuberculosis vaccine candidates following intranasal vaccination. PLoS One. 2011; 6(7):e22718. PMC: 3143185. DOI: 10.1371/journal.pone.0022718. View

13.

Saini D, Hopkins G, Seay S, Chen C, Perley C, Click E . Ultra-low dose of Mycobacterium tuberculosis aerosol creates partial infection in mice. Tuberculosis (Edinb). 2011; 92(2):160-5. PMC: 3288716. DOI: 10.1016/j.tube.2011.11.007. View

14.

Coulombe F, Fiola S, Akira S, Cormier Y, Gosselin J . Muramyl dipeptide induces NOD2-dependent Ly6C(high) monocyte recruitment to the lungs and protects against influenza virus infection. PLoS One. 2012; 7(5):e36734. PMC: 3348889. DOI: 10.1371/journal.pone.0036734. View

15.

Kleinnijenhuis J, Quintin J, Preijers F, Joosten L, Ifrim D, Saeed S . Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci U S A. 2012; 109(43):17537-42. PMC: 3491454. DOI: 10.1073/pnas.1202870109. View

16.

Chan P, Yang C, Chang L, Wang K, Kuo Y, Lin C . Lower prevalence of tuberculosis infection in BCG vaccinees: a cross-sectional study in adult prison inmates. Thorax. 2012; 68(3):263-8. DOI: 10.1136/thoraxjnl-2012-202208. View

17.

Eisenhut M . Enhanced innate immunity as explanation for reduced Mycobacterium tuberculosis infection in Bacillus Calmette-Guérin-immunized children. Am J Respir Crit Care Med. 2013; 188(2):257-8. DOI: 10.1164/rccm.201301-0060LE. View

18.

Ifrim D, Quintin J, Joosten L, Jacobs C, Jansen T, Jacobs L . Trained immunity or tolerance: opposing functional programs induced in human monocytes after engagement of various pattern recognition receptors. Clin Vaccine Immunol. 2014; 21(4):534-45. PMC: 3993125. DOI: 10.1128/CVI.00688-13. View

19.

Michelsen S, Soborg B, Koch A, Carstensen L, Hoff S, Agger E . The effectiveness of BCG vaccination in preventing Mycobacterium tuberculosis infection and disease in Greenland. Thorax. 2014; 69(9):851-6. DOI: 10.1136/thoraxjnl-2014-205688. View

20.

Roy A, Eisenhut M, Harris R, Rodrigues L, Sridhar S, Habermann S . Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis. BMJ. 2014; 349:g4643. PMC: 4122754. DOI: 10.1136/bmj.g4643. View